Topics:

Genentech cuts tape on melanoma combo trial

Tools

Roche's ($RHHBY) Genentech unit launched a new late-stage trial testing a two-drug combo in melanoma patients, throwing its hat in the ring with GlaxoSmithKline ($GSK), which is testing a rival combo therapy. Report